Current evidence showed that COPD subjects have increased pulmonary expression of angiotensin-converting enzyme 2 (ACE2) and transmembrane serine protease 2 (TMPRSS2) in lung tissues, which may predispose patients to an increased risk of worse outcomes from COVID-19 [2]. This evidence concerns the gene ACE2 and chronic obstructive pulmonary disease.